Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of XOMA 052 in Rheumatoid Arthritis
NCT00777816Phase 2Suspended
- Sponsor
- XOMA
- Start
- Feb 2009
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing XOMA 052 with Placebo (2 arms). Primary endpoint: Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and treatment-emergent adverse events. Started Feb 2009; status: suspended.
02
Drugs
gevokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00777816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777816.